Open

SAMURAI Study- Stereotactic radiation therapy with immune therapy for patients with Renal Cell Cancer

The purpose of this study is to compare the usual treatment of immune therapy alone to using radiation therapy with the usual treatment. The addition of radiation therapy to the usual treatment could stabilize your cancer or possibly cause it to shrink. This is a study for people with unresectable or metastatic renal cell cancer.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

North Carolina (Statewide)

What will be asked of you

If you decide to participate in this study, you will have CT scans and MRI's, blood draws, and physical exams.

In-person visits:
20+

Total length of participation:
10 years

Looking for Specific Volunteers

Able to participate:

You have a diagnosis of renal cell carcinoma
Kidney surgery was not recommended or you refused to have the surgery
You have adequate kidney function

Not eligible if:

You have received prior IV therapy for metastatic kidney cancer
You have planned surgery, radiation, or intervention to all metastatic cancer sites
You have untreated or unstable brain metastasis
You have an autoimmune disease that requires ongoing therapy with IV steroids

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Tracy Rose
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Kidney)

IRB Number

22-2989

ClinicalTrials.gov

NCT05327686

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.